Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on June 23, 2017, reporting an event that occurred on June 20, 2017. The registrant is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, or liquidity metrics. The only specific financial figure disclosed is the aggregate principal amount of $1.4 million under the Equipment Loan Agreement with Silicon Valley Bank (SVB).
Material Changes and Events
On June 20, 2017, the Company received a Notice of Event of Default from SVB regarding its $1.4 million Equipment Loan Agreement dated November 17, 2015. The notice cites continuing defaults under the following sections:
- Section 8.2(a) (Covenant Defaults) due to violations of Sections 7.1 and 7.2.
- Section 8.3 (Material Adverse Change).
- Section 8.6 (Other Agreements).
- Section 8.8 (Misrepresentations).
This event follows a similar Notice of Event of Default received on June 1, 2017, regarding a separate Loan Agreement with Oxford Finance LLC and SVB, which was disclosed in a prior Form 8-K on June 7, 2017.
Outlook, Risks, and Management Commentary
SVB stated in the Equipment Notice that it intends to monitor the default situation carefully and will decide on a "day-by-day" basis whether to exercise rights and remedies. The filing indicates significant liquidity and solvency risks due to the acceleration of debt obligations and the potential enforcement of remedies by the lender.
Investor Verification Checklist
- Verify the current status of the $1.4 million Equipment Loan Agreement and whether SVB has exercised any remedies.
- Confirm the status of the separate Loan Agreement with Oxford Finance LLC and SVB referenced in the June 7, 2017 filing.
- Review the Company's cash position and ability to meet covenant requirements or negotiate a waiver.
- Check for any subsequent filings regarding bankruptcy proceedings or debt restructuring.